![]() The drug works by attacking a toxic protein in the brain called amyloid. It was last year reported that it received more than £220,000 from drug firm Biogen, which helped to develop lecanemab. The calls have been led by leading US dementia charity the Alzheimer's Association, which has been accused of conflicts of interest and bias – which it vehemently denies. 'It is almost certain it will get the green light in June.' 'There is so much pressure on the authorities to deliver this drug, I don't think there's any way they can not approve lecanemab,' the former FDA adviser said. Experts investigating her death concluded the cause was a lethal seizure triggered by the drug.ĭespite this, lecanemab is expected to be approved by American health chiefs next month after lobbying from dementia campaigners. The MoS last month reported the case of one 79-year-old Florida woman who died suddenly after taking three doses of lecanemab as part of a medical trial. ![]() In a series of exclusive reports, The Mail on Sunday revealed that one in ten people who take the drug suffer life-threatening brain swelling, and one in six develop brain bleeds, according to data published by the pharmaceutical firm behind the drug.Īpproval of dementia medication – lecanemab – will 'cost lives, not just in the US, but in the UK and other countries, too,' a world-renowned dementia expert and former adviser to the US drug watchdog the Food and Drug Administration (FDA) warned The drug is a twice-a-month injection and was hailed as 'the beginning of the end for Alzheimer's' when early trial results unveiled in September showed it could slow the disease by a third.īut safety concerns have since emerged, leading many experts to say it should not be rolled out until more is known. The slate is set to start in 2025 with a new Batman and a new Superman.Leading scientists have hinted that American regulators are set to give a first-of-its-kind dementia jab the go-ahead – despite claims that it can trigger deadly bleeds in the brain.Ī world-renowned dementia expert and former adviser to the US drug watchdog the Food and Drug Administration ( FDA), who asked to remain anonymous, said he feared the decision could sway UK health chiefs to do the same.Īpproval of the medication – lecanemab – will 'cost lives, not just in the US, but in the UK and other countries, too,' he warned.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |